| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Surv |
| Uniprot No | O15392 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-142aa |
| 氨基酸序列 | MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHCPTEN EPDLAQCFFCFKELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGE FLKLDRERAKNKIAKETNNKKKEFEETAKKVRRAIEQLAAMD |
| 预测分子量 | 33 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Survivin(可能简写为Surv)重组蛋白的示例性参考文献，涵盖不同研究方向：
1. **《Recombinant Survivin protein expression and purification in Escherichia coli: Functional characterization of anti-apoptotic activity》**
- 作者：Altieri, D.C. 等
- 摘要：研究利用大肠杆菌表达系统高效表达并纯化重组Survivin蛋白，验证其在体外抑制细胞凋亡的功能，证实其通过结合caspase-3/7发挥抗凋亡作用。
2. **《Survivin recombinant protein enhances chemoresistance in breast cancer cells by modulating Bcl-2 family proteins》**
- 作者：Li, X. 等
- 摘要：探讨重组Survivin蛋白在乳腺癌细胞中对化疗药物耐药性的调控机制，发现其通过上调Bcl-2表达并抑制线粒体凋亡通路发挥作用。
3. **《Immunogenicity of a Survivin-based recombinant protein vaccine in a murine tumor model》**
- 作者：Siegel, S. 等
- 摘要：构建Survivin重组蛋白疫苗，证明其在动物模型中能诱导特异性T细胞免疫反应，显著抑制肿瘤生长并延长生存期。
4. **《Structural insights into Survivin recombinant protein dimerization and interaction with Smac/DIABLO》**
- 作者：Chantal, P. 等
- 摘要：通过X射线晶体学解析重组Survivin蛋白的二聚体结构，揭示其与凋亡相关蛋白Smac/DIABLO的结合界面，为靶向药物设计提供依据。
**注**：以上文献为示例性概括，具体研究需根据实际发表的论文调整。建议通过PubMed或Web of Science以“Survivin recombinant protein”为关键词检索最新文献。
**Background of Survivin Recombinant Protein**
Survivin, encoded by the *BIRC5* gene, is a member of the inhibitor of apoptosis (IAP) protein family, uniquely involved in regulating both cell survival and mitosis. It is characterized by a conserved baculovirus IAP repeat (BIR) domain, which mediates interactions with other cellular components. Survivin is predominantly expressed during embryonic development but is undetectable in most terminally differentiated adult tissues. However, it is re-expressed in numerous human cancers, correlating with tumor progression, therapy resistance, and poor prognosis. This cancer-specific expression profile makes Survivin a compelling biomarker and therapeutic target.
Recombinant Survivin protein is engineered using molecular cloning techniques, often expressed in bacterial (e.g., *E. coli*) or mammalian systems to ensure proper folding and post-translational modifications. The recombinant form retains functional domains, including the BIR domain critical for binding caspases (e.g., caspase-3 and -7) to inhibit apoptosis, and a coiled-coil domain that facilitates its role in mitosis by interacting with microtubules during chromosomal segregation.
In research, Survivin recombinant protein is utilized to study its molecular mechanisms, screen inhibitory compounds (e.g., small molecules, peptides), and develop targeted therapies. It also aids in antibody production for diagnostic assays. Therapeutic strategies targeting Survivin include antisense oligonucleotides, RNA interference, and immunotherapies, though clinical success remains limited, emphasizing the need for deeper mechanistic insights.
Overall, Survivin recombinant protein serves as a vital tool for dissecting its dual roles in apoptosis evasion and mitotic regulation, offering pathways to novel cancer treatments.
×
